Unknown

Dataset Information

0

Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor-Positive Breast Cancer.

ABSTRACT: To investigate the impact of sampling methodology on gene expression data from primary estrogen receptor-positive (ER+) breast cancer biopsies, global gene expression was measured in core-cut biopsies at baseline and surgery from patients randomly assigned to receive either two weeks of presurgical aromatase inhibitor (AI; n = 157) or no presurgical treatment (n = 56). Those genes most markedly altered in the AI group (eg, FOS, DUSP1, RGS1, FOSB) were similarly altered in the no treatment group; some widely investigated genes that were apparently unaffected in the AI group (eg, MYC) were counter-altered in the control group, masking actual AI-dependent changes. In the absence of a control group, these artefactual changes would likely lead to the most affected genes being the erroneous focus of research. The findings are likely relevant to all archival collections of ER+ breast cancer.

SUBMITTER: Gao Q 

PROVIDER: S-EPMC6649758 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

To investigate the impact of sampling methodology on gene expression data from primary estrogen receptor-positive (ER+) breast cancer biopsies, global gene expression was measured in core-cut biopsies at baseline and surgery from patients randomly assigned to receive either two weeks of presurgical aromatase inhibitor (AI; n = 157) or no presurgical treatment (n = 56). Those genes most markedly altered in the AI group (eg, <i>FOS</i>, <i>DUSP1</i>, <i>RGS1</i>, <i>FOSB</i>) were similarly altere  ...[more]

Similar Datasets

Transcriptomics Major impact of sampling methodology on gene expression in estrogen receptor positive breast cancer
2018-10-22 | GSE105777 | GEO
Genomics Major impact of sampling methodology on gene expression in estrogen receptor positive breast cancer
| PRJNA415551 | ENA
Unknown The impact of CBP expression in estrogen receptor-positive breast cancer.
| S-EPMC8028106 | biostudies-literature
Unknown Identification of gene expression signature in estrogen receptor positive breast carcinoma.
| S-EPMC3783308 | biostudies-literature
Unknown Estrogen independent gene expression defines clinically relevant subgroups of estrogen receptor positive breast cancer.
| S-EPMC4289221 | biostudies-literature
Unknown PARP-1 Regulates Estrogen-Dependent Gene Expression in Estrogen Receptor α-Positive Breast Cancer Cells.
| S-EPMC8492518 | biostudies-literature
Unknown Gene expression profiles of estrogen receptor-positive and estrogen receptor-negative breast cancers are detectable in histologically normal breast epithelium.
| S-EPMC3059257 | biostudies-literature
Unknown Progesterone Receptor Gene Variants in Metastatic Estrogen Receptor Positive Breast Cancer.
| S-EPMC7152560 | biostudies-literature
Unknown An mRNA Gene Expression-Based Signature to Identify FGFR1-Amplified Estrogen Receptor-Positive Breast Tumors.
| S-EPMC5225309 | biostudies-literature
Unknown Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women.
| S-EPMC2834467 | biostudies-literature